Fundz

Hepion Pharmaceuticals

EDISON, NJ · Biotechnology · 22 employees

Hepion Pharmaceuticals (Nasdaq: HEPA) is a biopharmaceutical company focused on the development of pleiotropic drug therapy for treatment of chronic liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis, and other liver diseases. Our cyclophilin inhibitor, CRV431, is being developed to offe

Funding history

  • Series seed — $700K — Apr 2026
  • Funding Round — $2.9M — Jul 2024
  • Funding Round — $5.0M — Oct 2023
  • Funding Round — $20.0M — Nov 2022
  • Series seed — $1.3M — Mar 2019

Recent signals

  • Apr 22, 2026: Raised $700K in Series seed
  • Mar 03, 2026: Hepion Pharmaceuticals Enters License Agreement with Cirna Diagnostics
  • Feb 25, 2026: SEC 8-K (1.01): On February 25, 2026, Hepion Pharmaceuticals, Inc. entered into an intellectual property license agreement with Cirna Diagnostics, LLC. The agreement allows Hepion to license certain liver disease diagnostic assets, which includes an upfront payment of $50,000 and up to $2,350,000 in milestone payments, in addition to sales milestone payments of up to $4,500,000 and a low single-digit royalty on net sales. This strategic partnership aims to enhance Hepion's capabilities in early diagnosis of hepatocellular carcinoma, providing significant long-term benefits in the liver disease diagnostic space.
  • Jan 03, 2026: SEC 8-K (5.02): On January 13, 2026, Hepion Pharmaceuticals, Inc. announced the appointment of Dr. Kaouthar Lbiati as Chief Executive Officer under a new employment agreement effective from January 8, 2026. According to the Lbiati Employment Agreement, Dr. Lbiati will receive a base salary of $350,000 along with an annual cash discretionary bonus with a target amount equal to 35% of her base salary, dependent on the achievement of certain goals set by the Board of Directors. This strategic management change is expected to influence the company's operations and direction significantly, as Dr. Lbiati steps into a crucial leadership role at a pivotal time.
  • Jul 24, 2024: Raised $2.9M
  • Oct 03, 2023: Raised $5.0M
  • Nov 15, 2022: Raised $20.0M
  • Mar 27, 2019: Raised $1.3M in Series seed

See plans & pricing → Track Hepion Pharmaceuticals’s funding, hiring, and signals — with verified contacts — on Fundz.